Perioperative treatment with cilostazol reverses steatosis and improves liver regeneration after major hepatectomy in a steatotic rat model

Bibliographic Details
Title: Perioperative treatment with cilostazol reverses steatosis and improves liver regeneration after major hepatectomy in a steatotic rat model
Authors: Sebastian Holländer, Maximilian von Heesen, Gereon Gäbelein, Julie Mercier, Matthias W. Laschke, Michael D. Menger, Matthias Glanemann, Antonios E. Spiliotis
Source: Scientific Reports, Vol 15, Iss 1, Pp 1-13 (2025)
Publisher Information: Nature Portfolio, 2025.
Publication Year: 2025
Collection: LCC:Medicine
LCC:Science
Subject Terms: Obesity, Non-alcoholic fatty liver disease, Hepatectomy, Cilostazol, Liver regeneration, Medicine, Science
More Details: Abstract Cilostazol has previously been shown to reduce liver steatosis and enhance hepatic perfusion. We investigated the effects of cilostazol after major hepatectomy in a steatotic rat model. Six weeks prior to surgery, Sprague–Dawley rats were fed with a high-fructose diet. The treatment group received daily 5 mg/kg cilostazol. Seven days following the cilostazol treatment, all animals underwent 70% liver resection (PHX). Analysis of hepatic blood flow and microcirculation and immunohistochemical examinations were conducted 30 min after PHX (postoperative day [POD] 0) as well as on POD 1, POD 3 and POD 7. The weight of cilostazol-treated animals was significantly reduced compared to untreated controls after completion of the 6-week high-FRC diet. Furthermore, 41% macrovesicular steatosis was found in the control group compared to 8% in the cilostazol group. Hepatic arterial and portal venous perfusion were increased in the cilostazol group on POD 7. Lower liver enzyme release was found postoperatively in cilostazol-treated animals. Moreover, apoptosis and neutrophil infiltration were reduced after cilostazol treatment. Proliferation of hepatocytes and liver regeneration after PHX were significantly increased in the cilostazol group. Consequently, cilostazol should be evaluated as a novel strategy to reduce the rate of liver failure after PHX in steatotic liver.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2045-2322
Relation: https://doaj.org/toc/2045-2322
DOI: 10.1038/s41598-025-87135-z
Access URL: https://doaj.org/article/6facd203b5a24b52bf51325aa9968efc
Accession Number: edsdoj.6facd203b5a24b52bf51325aa9968efc
Database: Directory of Open Access Journals
More Details
ISSN:20452322
DOI:10.1038/s41598-025-87135-z
Published in:Scientific Reports
Language:English